<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-two patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated with thalidomide plus <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> (ATO) </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients receiving supportive care were used as controls </plain></SENT>
<SENT sid="2" pm="."><plain>The remission was achieved in 4 patients (18.2%) receiving thalidomide/ATO, and none in the control group (p&lt;0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen of 22 patients in the treatment group achieved hematologic improvement (68.2% vs. 27.3% in the control, p&lt;0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>The progression-free survival was longer in the treatment group than that in the control (26 vs. 10 months, p&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The overall survival was also longer in the treatment group than that in the control (36 vs. 16 months, p&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>No severe adverse reactions were observed </plain></SENT>
<SENT sid="7" pm="."><plain>These preliminary findings suggest that thalidomide/ATO combination treatment is effective and safe for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>